Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension of GNC-003 with GNbAC1 in relapsing-remitting multiple sclerosis
2016-004935-18Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temelimab in relapsing-remitting multiple sclerosis (RRMS), sponsored by GeNeuro. Primary endpoint: Long-term safety of GNbAC1. Started Feb 2017; status: completed.
02
Drugs
temelimab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-004935-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004935-18.